Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-14T07:00:28.024Z Has data issue: false hasContentIssue false
  • English
  • Français

Cambio en la intensidad del dolor con venlafaxina administrada de forma abierta en pacientes con sintomatología depresiva: estudio de observación en la atención primaria

Published online by Cambridge University Press:  12 May 2020

Stefan Begré ,
Martin Traber ,
Martin Gerber  and
Roland von Känel
Stefan Begré
Affiliation:
Departamento de Medicina Interna, División de Medicina Psicosomática, Hospital Universitario/Inselspital, CH-3010Berna, Suiza
Martin Traber
Affiliation:
Laboratorios Wyeth AG, Grafenauweg 10, CH-6301Zug, Suiza
Martin Gerber
Affiliation:
GEM Clinical Research Consulting M. Gerber, Gewerbestrasse 6, CH-6314Unterägeri/ZG, Suiza
Roland von Känel
Affiliation:
Departamento de Medicina Interna, División de Medicina Psicosomática, Hospital Universitario/Inselspital, CH-3010Berna, Suiza
Get access

Resumen

Objetivo

Venlafaxina ha demostrado ser eficaz en el tratamiento de la depresión y del dolor. Carecemos de datos sobre el resultado de los pacientes con dolor crónico y síntomas depresivos tratados con venlafaxina en el marco de la atención primaria. Este estudio de observación intentó definir la eficacia de venlafaxina y su prescripción por los médicos de atención primaria y psiquiatras suizos en pacientes con dolor crónico y sintomatología depresiva.

Sujetos y métodos

Estudiamos a 505 pacientes con síntomas depresivos que sufrían dolor crónico en un estudio prospectivo naturalista de observación con venlafaxina en la atención primaria suiza. Estos pacientes fueron tratados con venlafaxina por 122 médicos (psiquiatras, médicos generalistas e internistas).

Resultados

Por término medio, los pacientes recibieron con 143 ± 75 mg (0-450 mg) de venlafaxina al día durante tres meses. Venlafaxina demostró ser eficaz tanto en el tratamiento de los síntomas depresivos como del dolor crónico.

Discusión

Aunque no se observaron efectos secundarios en la mayor parte de los pacientes, posiblemente no se consiguió una respuesta satisfactoria de la depresión por administrar dosis bajas de venlafaxina. Nuestros resultados reflejan la complejidad del tratamiento de dolor crónico en pacientes con síntomas depresivos en la atención primaria.

Conclusión

Son necesarios nuevos estudios aleatorizados que determinen la dosis apropiada de venlafaxina para el tratamiento de la depresión y del dolor coexistente.

Keywords

DolorDepresión unipolarAntidepresivoPsiquiatría en EuropaSuizaAtención primariaVenlafaxinaAtención clínica
Type
Artículo original
Information
European Psychiatry (Ed. Española) , Volume 15 , Issue 6 , September 2008 , pp. 298 - 307
Copyright
Copyright © European Psychiatric Association 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

[1]American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed.; 1994.Google Scholar
[2]Ansari, AThe efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harv Rev Psychiatry 2000;7(5):257–77.CrossRefGoogle ScholarPubMed
[3]Arnow, BAHunkeler, EMBlasey, CMLee, JConstantino, MJFire-, man B et al. Comorbid depression, chronic pain, disability in primary care. Psychosom Med 2006;68(2):262–8.CrossRefGoogle ScholarPubMed
[4]Bagby, RMRyder, AGSchuller, DRMarshall, MBThe Hamilton depression rating scale: has the gold standard become a lead weight? Am J Psychiatry 2004; 161(12):2163–77.CrossRefGoogle ScholarPubMed
[5]Bair, MJRobinson, RLKaton, WKroenke, KDepression and pain comorbidity: a literature review. Arch Intern Med 2003;163 (20):2433–45.CrossRefGoogle ScholarPubMed
[6]Bair, MJRobinson, RLEckert, GJStang, PECroghan, TWKroenke, KImpact of pain on depression treatment response in primary care. Psychosom Med 2004;66(1): 17–22.CrossRefGoogle ScholarPubMed
[7]Bandelow, BBaldwin, DSDolberg, OTAndersen, HFStein, DJWhat is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder? J Clin Psychiatry 2006;67(9): 1428–34.CrossRefGoogle ScholarPubMed
[8]Bradley, RHBarkin, RLJerome, JDe Young, K, Dodge, CW. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003; 10(5):318–23.CrossRefGoogle Scholar
[9]Bryson, HMWilde, MIAmitriptyline. A review of its pharmacolo- gical properties and therapeutic use in chronic pain states. Drugs Aging 1996;8(6):459–76.Google ScholarPubMed
[10]Debonnel, GSaint-Andre, EHebert, Cde Montigny, C, Lavoie, N, Blier, P. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 2007; 10(1):51 -61.CrossRefGoogle ScholarPubMed
[11]Dick, IEBrochu, RMPurohit, YKaczorowski, GJMartin, WJPriest, BTSodium channel blockade may contribute to the analgesic effi- cacy of antidepressants. J Pain 2007;8(4):315–24.CrossRefGoogle Scholar
[12]Enggaard, TPKlitgaard, NAGram, LFArendt-Nielsen, LSindrup, SHSpecific effect of venlafaxine on single and repetitive experi- mental painful stimuli in humans. Clin Pharmacol Ther 2001,69(4): 245–51.CrossRefGoogle Scholar
[13]Fishbain, DACutler, RRosomoff, HLRosomoff, RSEvidence- based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med 2000; 1(4): 310–6.CrossRefGoogle ScholarPubMed
[14]Freeman, EWRickels, KYonkers, KAKunz, NRMcPherson, MUpton, GVVenlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001;98(5 Pt l):737–44.Google ScholarPubMed
[15]Gureje, OPsychiatric aspects of pain. Curr Opin Psychiatry 2007;20(1):42–6.CrossRefGoogle ScholarPubMed
[16]Gutierrez, MAStimmel, GLAiso, JYVenlafaxine: a 2003 update. Clin Ther 2003;25(8):2138–54.CrossRefGoogle ScholarPubMed
[17]Guy, WECDEU assessment manual for psychopharmacology. Revised ed.). Rockville: National Institute for Mental Health; 1976.Google Scholar
[18]Hamilton, MA rating scale for depression. J Neurol Neurosurg Psychiatr 1960;23:56–62.CrossRefGoogle ScholarPubMed
[19]Harvey, ATRudolph, RLPreskorn, SHEvidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000;57(5): 503–9.CrossRefGoogle ScholarPubMed
[20]Janea, AHiller, WICD-10 checklists - a tool for clinicians' use of the ICD-10 classification of mental and behavioral disorders. Compr Psychiatry 1996;37(3): 180–7.Google Scholar
[21]Karp, JFVenlafaxine XR and chronic pelvic pain syndrome. J Clin Psychiatry 2004;65(6):880–1.CrossRefGoogle ScholarPubMed
[22]Khalifa, MDaleau, PTurgeon, JMechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999;291(1):280–4.Google ScholarPubMed
[23]Kroenke, KMessina, III NBenattia, IGraepel, JMusgnung, JVenlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiatry 2006;67(1):72–80.CrossRefGoogle ScholarPubMed
[24]Max, MBTreatment of post-herpetic neuralgia: antidepressants. Ann Neurol 1994;35(Suppl.):S50–3.CrossRefGoogle ScholarPubMed
[25]Max, MBLynch, SAMuir, JShoaf, SESmoller, BDubner, REffects of desipramine, amitriptyline, fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326(19): 1250–6.CrossRefGoogle ScholarPubMed
[26]Mbaya, PSafety and efficacy of high dose of venlafaxine XL in treatment resistant major depression. Hum Psychopharmacol 2002;17(7):335–9.CrossRefGoogle ScholarPubMed
[27]Montauk, SLMartin, JTreating chronic pain. Am Fam Physician 1997;55(4):1151–6.Google ScholarPubMed
[28]Murray, CJLopez, ADAlternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997;349(9064): 1498–504.CrossRefGoogle ScholarPubMed
[29]Nierenberg, AAFeighner, JPRudolph, RCole, JOSullivan, JVenlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14(6):419–23.CrossRefGoogle ScholarPubMed
[30]Ozyalcin, SNTala, GKKiziltan, EYucel, BErtas, MDisci, RThe efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005;45(2): 144–52.CrossRefGoogle ScholarPubMed
[31]Reuben, SSThe prevention of post-surgical neuralgia. Pain 2005;113(l-2):242–3.CrossRefGoogle ScholarPubMed
[32]Rowbotham, MCGoli, VKunz, NRLei, DVenlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo controlled study. Pain 2004; 110(3):697–706.CrossRefGoogle ScholarPubMed
[33]Rudolph, RLFabre, LFFeighner, JPRickels, KEntsuah, RDerivan, ATA randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998;59(3): 116–22.CrossRefGoogle ScholarPubMed
[34]Saarto, TWiffen, PJAntidepressants for neuropathic pain. Cochrane Database Syst Rev 2005;(3). CD005454.CrossRefGoogle ScholarPubMed
[35]Sayar, KAksu, GAk, ITosan, MVenlafaxine treatment of fibromyalgia. Ann Pharmacother 2003;37(11): 1561–5.CrossRefGoogle ScholarPubMed
[36]Sindrup, SHOtto, MFinnerup, NBJensen, TSAntidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005; 96(6):399–409.CrossRefGoogle ScholarPubMed
[37]Sindrup, SHGram, LFSkjold, TFroland, ABeck-Nielsen, HConcentration- response relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther 1990;47(4):509–15.CrossRefGoogle ScholarPubMed
[38]Sir, AD'Souza, RFUguz, SGeorge, TVahip, SHopwood, M et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005;66(10): 1312–20.CrossRefGoogle ScholarPubMed
[39]Stahl, SMGrady, MMMoret, CBriley, MSNRIs: their pharmacology, clinical efficacy, tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10(9):732–47.CrossRefGoogle ScholarPubMed
[40]Staiger, TOGaster, BSullivan, MDDeyo, RASystematic review of antidepressants in the treatment of chronic low bock pain. Spine 2003;28(22):2540–5.CrossRefGoogle Scholar
[41]Songer, DASchulte, HVenlafaxine for the treatment of chronic pain. Am J Psychiatry 1996;153(5):737.Google ScholarPubMed
[42]Thase, MEEffects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59(10):502–8.CrossRefGoogle ScholarPubMed
[43]Thase, METreatment of anxiety disorders with venlafaxine XR. Expert Rev Neurother 2006;6(3):269–82.CrossRefGoogle ScholarPubMed
[44]Van Os, TW, Van den Brink, RH, Van der, MK, Ormel, J. The care provided by general practitioners for persistent depression. Eur Psychiatry 2006;21(2):87–92.CrossRefGoogle ScholarPubMed
[45]Wang, GKRussell, CWang, SYState-dependent block of voltagegated Na+ channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain. Pain 2004;110(l-2):166–74.CrossRefGoogle Scholar
[46]Wellington, KPerry, CMVenlafaxine extended-ralease: a review of its use in the management of major depression. CNS Drugs 2001;15(8):643–69.CrossRefGoogle ScholarPubMed
[47]Zissis, NPHarmoussi, SVlaikidis, NMitsikostas, DThomaidis, TGeorgiadis, G et al. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia 2007;27(4):315–24.CrossRefGoogle ScholarPubMed